Individuals with acute myeloid leukemia (AML) harboring an internal tandem duplication (ITD) in the gene encoding Fms-related tyrosine kinase 3 (FLT3) who relapse after allogeneic hematopoietic cell transplantation (allo-HCT) have a 1-year survival rate below 20%. We observed that sorafenib, a multitargeted tyrosine kinase inhibitor, increased IL-15 production by FLT3-ITD + leukemia cells. This synergized with the allogeneic CD8 + T cell response, leading to long-term survival in six mouse models of FLT3-ITD + AML. Sorafenib-related IL-15 production caused an increase in CD8 + CD107a + IFN-γ + T cells with features of longevity (high levels of Bcl-2 and reduced PD-1 levels), which eradicated leukemia in secondary recipients. Mechanistically, sorafenib reduced expression of the transcription factor ATF4, thereby blocking negative regulation of interferon regulatory factor 7 (IRF7) activation, which enhanced IL-15 transcription. Both IRF7 knockdown and ATF4 overexpression in leukemia cells antagonized sorafenib-induced IL-15 production in vitro. Human FLT3-ITD + AML cells obtained from sorafenib responders following sorafenib therapy showed increased levels of IL-15, phosphorylated IRF7, and a transcriptionally active IRF7 chromatin state. The mitochondrial spare respiratory capacity and glycolytic capacity of CD8 + T cells increased upon sorafenib treatment in sorafenib responders but not in nonresponders. Our findings indicate that the synergism of T cells and sorafenib is mediated via reduced ATF4 expression, causing activation of the IRF7-IL-15 axis in leukemia cells and thereby leading to metabolic reprogramming of leukemia-reactive T cells in humans. Therefore, sorafenib treatment has the potential to contribute to an immune-mediated cure of FLT3-ITD-mutant AML relapse, an otherwise fatal complication after allo-HCT.
analogous to donor lymphocyte infusions (DLI) in patients. We observed long-term control of leukemia only in mice receiving both sorafenib and T cells. Sorafenib was not protective when administered alone (Fig. 1a) . A comparable pattern of leukemia control was observed using a mouse model of lymphoblastic leukemia (in which mice are injected with the mouse Ba/F3-ITD cell line) with respect to survival (Fig. 1b) and expansion of luciferase reporter (LUC) + GFP + leukemia cells (Fig. 1c-e and Supplementary Fig. 1a) . Microarraybased analysis of Ba/F3-ITD cells revealed that IL-15 (Il15) mRNA was upregulated upon sorafenib exposure in vitro (Fig. 1f,g ), which was confirmed through qPCR and flow cytometry (Fig. 1h,i) . IL-15 production was dependent on sorafenib sensitivity, as Ba/F3 cells expressing the sorafenib-resistant FLT3-ITD-F691L mutant showed no increase in IL-15 expression following sorafenib treatment (Fig. 1i) .
IL-15 levels were higher in serum from mice that were treated with T cells and sorafenib than in vehicle-treated mice (Fig. 1j) . This sorafenib-induced increase in serum IL-15 subsided with reduced numbers of leukemia cells at a later time point during treatment (Fig. 1j) . IL-15 serum levels increased upon FLT3-ITD inhibition in additional mouse models of myeloid leukemia (including models in which mice were injected with bone marrow (BM) cells transfected with FLT3-ITD or the mouse myeloid WEHI-3B FLT3-ITD cell line, and the genetic model driven by the Mll PTD/+ and Flt3 ITD/+ mutations 13 ) Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITDmutant leukemia cells ITDs in the gene encoding the FLT3 receptor tyrosine kinase are found in 20-25% of AML cases and provide a stimulus for persistent leukemia cell proliferation. Because of the unfavorable prognosis of FLT3-ITD + AML, most patients undergo allo-HCT 1,2 . FLT3-ITD + AML relapse after allo-HCT is not curable in the majority of patients. Sorafenib is a multitargeted tyrosine kinase inhibitor that can reduce the proliferation and survival of FLT3-ITD + AML cells in vitro. Although sorafenib treatment did not improve the overall survival (OS) of patients with AML when combined with standard chemotherapy 3, 4 , it caused durable remission in some patients with FLT3-ITD + AML after allo-HCT [5] [6] [7] , thereby prompting trials of sorafenib maintenance therapy [8] [9] [10] [11] . However, the mechanism by which sorafenib combined with allogeneic immunity may induce long-term control of FLT3-ITD + AML remains unknown.
RESULTS

Sorafenib induces IL-15 production by FLT3-ITD + AML cells
To understand whether a functional synergism between allogeneic immune responses and sorafenib occurs, we used a mouse leukemia model 12 in which one allele of mixed-lineage leukemia (Mll) has a partial tandem duplication (Mll PTD/+ ) and one Flt3 allele has the ITD mutation (Flt3 ITD/+ ) (Fig. 1a) . Leukemia cells from these mice were infused into recipient mice after irradiation and allo-HCT and 2 d after allo-HCT donor-derived T cells were infused, in a procedure ; n values represent biologically independent samples. P values were calculated using the two-sided Student's unpaired t-test. (h) Quantification of Il15 mRNA expression through qPCR in Ba/F3-ITD leukemia cells treated with 10 nM sorafenib or DMSO relative to Mon2 mRNA expression. The experiment was performed three times, and the results (mean ± s.e.m.) were pooled; n values represent biologically independent samples. P values were calculated using the two-sided Student's unpaired t-test. (i) Quantification of intracellular IL-15 (fold change in the mean fluorescence intensity (MFI) of IL-15 with respect to the mean MFI of IL-15 in DMSO-treated controls). Ba/F3-ITD cells (sorafenib sensitive) and Ba/F3-ITD-F691L cells (harboring a mutation in FLT3 conferring sorafenib resistance) were studied. The experiment was performed three times, and the results (mean ± s.e.m.) were pooled; n values represent biologically independent samples, and each data point represents a measurement from a biologically independent sample. P values were calculated using the two-sided Student's unpaired t-test. (j) Quantification of serum IL-15 and IL-15Rα from naive BALB/c mice or BALB/c recipients transplanted with C57BL/6 BM and Ba/F3-ITD leukemia cells with additional C57BL/6 T cells and treated with vehicle or sorafenib on day 14, day 22, or day 98 following intravenous (i.v.) injection of Ba/F3-ITD cells. The dashed line represents the detection limit (4 pg/ml) for the mouse IL-15 and IL-15Rα ELISA. The experiment was performed three times (except one time for the day 98 group), and the results (mean ± s.e.m.) were pooled; n values represent biologically independent samples, and each data point represents a measurement from a biologically independent sample derived from an individual mouse. P values were calculated using a two-sided Mann-Whitney U test.
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A r t i c l e s (i,j) Expression of Bcl-2 (i) and PD-1 (j) (quantified as fold change in the MFI with respect to the mean MFI for the vehicle-treated group) in all H-2kb + CD8 + T cells from BMT mice transplanted with Ba/F3-ITD cells and treated with vehicle or sorafenib as indicated or from untreated naive C57BL/6 mice. Each data point represents an individual sample of one biologically independent animal. The experiment was performed three times, and the results (mean ± s.e.m.) were pooled; n values represent biologically independent mice. P values were calculated using a two-sided Mann-Whitney U test (i) or a two-sided Student's unpaired t-test (j).
( Supplementary Fig. 1b-d) . Sorafenib had no effect on T cell activation in vitro ( Supplementary Fig. 1e-h ). Leukemia cells expressed IL-15 receptor subunit α (IL-15Rα; Supplementary Fig. 1i ,j), which is essential for IL-15 transpresentation 14 .
Genetic deficiency for IL-15 in FLT3-ITD + leukemia cells abrogated the beneficial effects of sorafenib, whereas IL-15 deficiency of the recipient mouse did not (Fig. 2a,b) . Lack of IL-15 in leukemia cells could be rescued by exogenous IL-15 (Fig. 2b) normalized to that of β-actin (quantified as the fold change with respect to DMSO-treated controls) in mouse Ba/F3-ITD (a) or human FLT3-ITD + MV4-11 (b) leukemia cells exposed to sorafenib as indicated. The experiments were performed three times, and the results (mean ± s.e.m.) were pooled; n values represent biologically independent samples. P values were calculated using the two-sided Mann-Whitney U test. (c) Western blots showing the levels of p-IRF7, t-IRF7, and loading control (β-actin) in Ba/F3-ITD leukemia cells exposed to sorafenib. All uncropped western blots are shown in Supplementary  Figures 15-21. (d) Quantification of p-IRF7 to t-IRF7 ratio normalized to the level of β-actin (quantified as fold change with respect to DMSO-treated controls) in Ba/F3-ITD cells treated as indicated. The experiment was performed four times, and the results (mean ± s.e.m.) were pooled; n values represent biologically independent samples, and each data point represents an individual sample of one independent cell culture experiment. P values were calculated using the two-sided Mann-Whitney U test. (e) Representative western blots showing the levels of p-IRF7, t-IRF7, and loading control (β-actin) in MV4-11 cells treated with the indicated sorafenib concentrations for 24 h. (f) Fold change of intracellular IL-15 (MFI) in Ba/F3-ITD cells or Ba/F3-ITD cells transfected with a lentiviral vector overexpressing mouse ATF4 and treated with sorafenib (0.1 µM) as indicated for 24 h. Fold change is relative to DMSO treatment, which is set as '1'. The experiment was performed three times, and results (mean ± s.e.m.) were pooled; n values represent biologically independent samples, and each data point represents an individual sample of one independent cell culture experiment. P values were calculated using the two-sided Mann-Whitney U test. (g) Percentage survival of BALB/c mice transplanted with C57BL/6 BM and ATF4-overexpressing Ba/F3-ITD cells or Ba/F3-ITD cells with endogenous ATF4 expression (Ba/F3-ITD ATF4-Tg and Ba/F3-ITD, respectively; n = 500 cells) with additional C57BL/6 T cells (2 × 10 5 , administered on day 2) and treated with vehicle or sorafenib. The experiment was performed twice, and the results were pooled; n values represent biologically independent mice. P values were calculated using the two-sided Mantel-Cox test. (h) Quantification of IL15 mRNA through qPCR in human MOLM-13 (FLT3-ITD + AML) cells expressing a nonsilencing vector (MOLM-13 NS shRNA ) or an IRF7-knockdown vector (MOLM-13 IRF7 shRNA ). MOLM-13 cells were exposed to the indicated concentrations of sorafenib. The experiment was performed twice, and the results (mean ± s.e.m.) were pooled; n values represent biologically independent samples. P values were calculated using the two-sided Mann-Whitney U test. (i) Percentage survival of Rag2 −/− Il2ra −/− mice transplanted with MOLM-13 NS shRNA or MOLM-13 IRF7 shRNA cells as indicated. The experiment was performed twice, and the results were pooled; n values represent biologically independent mice. The P value was calculated using a two-sided Mantel-Cox test. (j) Proposed mechanism through which sorafenib leads to increased IL-15 transcription. Sorafenib inhibits FLT3 receptor tyrosine kinase signaling, which normally leads to ATF4 production. Reduced ATF4 levels result in less inhibition of IRF7 phosphorylation and activation. Active p-IRF7 can translocate to the nucleus, where it activates IL-15 transcription.
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in increased lethality (Fig. 2a) due to more severe graft-versus-host disease (GVHD), which was not observed in sorafenib-treated mice (Fig. 2c) . These data indicate that the level of IL-15 production by leukemia cells following sorafenib exposure was below the threshold required to drive a GVHD response. Antibody-based IL-15 depletion or transfer of Il15ra-deficient T cells to recipient mice caused loss of leukemia control despite sorafenib treatment (Fig. 2d-f) . The sorafenib-T cell combination improved survival in recipient mice transfused with leukemia cells from three humanized models in which mice were injected with primary human FLT3-ITD + AML cells or cells from the MV4-11 or MOLM-13 human cell line (both of which are FLT3-ITD + AML cell lines) (Fig. 2g-i) .
T cells from sorafenib-treated mice exhibit an activated phenotype and reject leukemia cells in secondary recipients Expression of the antitumor cytotoxicity marker 15 CD107a, interferon (IFN)-γ, and CD40 ligand (CD40L) was higher in donor CD8 + T cells in allo-HCT recipients that had been treated with sorafenib than in those that were treated with vehicle ( Fig. 3a-c and Supplementary Fig. 2a,b) . Treatment with IL-15 increased the frequency of CD8 + CD107a + T cells in vitro as compared to vehicle treatment ( Supplementary Fig. 2c,d) . IL-15R activation leads to signal transducer and activator of transcription 5 (STAT5) phosphorylation 16 , and higher levels of phosphorylated STAT5 (p-STAT5) were found in CD8 + T cells derived from sorafenib-treated mice (Fig. 3d) . Depletion of CD8 + T cells, but not natural killer (NK) cells (Supplementary Fig. 2e ), in grafts caused loss of the protective effect of sorafenib (Fig. 3e) , indicating that CD8 + T cells mediate the sorafenib-induced antitumor effect.
To understand whether recall immunity developed under sorafenib treatment, we next isolated CD8 + H-2Kb + T cells from mice transfused with Ba/F3-ITD leukemia cells that had been treated with T cells and either vehicle or sorafenib (Supplementary Fig. 2f ). We transplanted these cells into secondary recipients of Ba/F3-ITD leukemia cells, finding that CD8 + H-2Kb + T cells isolated from allo-HCT recipients that had been treated with sorafenib, but not those from mice treated with vehicle or with anti-IL-15 antibody in addition to sorafenib, caused long-term control in secondary recipients (Fig. 3f-h) . Donor T cells from sorafenib-treated primary recipients exhibited features of longevity 17, 18 , including high expression of B cell lymphoma 2 (Bcl-2) and reduced programmed cell death protein 1 (PD-1) expression (Fig. 3i,j) .
The target specificity of the recall immune response was reflected by the fact that T cells isolated from sorafenib-treated primary recipients bearing leukemia cells of the Ba/F3-ITD line did not control leukemia resulting from WEHI-3B cells from third-party donors in secondary recipients (Supplementary Fig. 2g-i) . In vitro IL-15 production was not seen in FLT3-ITD − leukemia cell lines upon sorafenib exposure (Supplementary Fig. 3a,b) , and FLT3-ITD − WEHI-3B cells could not induce recall immunity (Supplementary Fig. 3c,d ).
Sorafenib induces IL-15 production via ATF4 inhibition IRF7 is an essential upstream activator of IL-15 transcription 19, 20 . Activating transcription factor-4 (ATF4) blocks IRF7 phosphorylation and activation 21 , thereby preventing IL-15 transcription. We observed reduced levels of Atf4 mRNA and ATF4 protein in mouse and human cells with FLT3-ITD-driven leukemia, but not in sorafenib-resistant FLT3-ITD + or FLT3-ITD − leukemia cells, upon sorafenib exposure (Fig. 4a,b and Supplementary Fig. 4a-f) . In accordance with the hypothesis of decreased negative regulation by ATF4 in FLT3-ITD + leukemia cells, the amount of active IRF7 (assessed by p-IRF7 and total IRF7 (t-IRF7, meaning unphosphorylated IRF7)) increased upon sorafenib treatment in mouse and human FLT3-ITD + leukemia cells (Fig. 4c-e and Supplementary Fig. 4g ), but not in sorafenib-resistant FLT3-ITD + leukemia cells (Supplementary Fig. 4h ). The increased IL-15 production (Fig. 4f), IRF7 activation (Supplementary Fig. 4i,j) , extended survival (Fig. 4g) , and reduced counts of leukemia cells in peripheral blood (Supplementary Fig. 4k ) resulting from sorafenib treatment were abrogated by ATF4 overexpression in leukemia cells (Supplementary Fig. 4l ). IRF7 knockdown in leukemia cells (Supplementary Fig. 4m ) caused reduced levels of IL-15 production by human FLT3-ITD + AML cells in vitro and loss of extended survival upon sorafenib treatment in vivo (Fig. 4h,i) .
Kinome analysis and subsequent kinase inhibition of human FLT3-ITD + AML cells revealed the selective impact of sorafenib on IL-15 production (Supplementary Figs. 5 and 6) . Analysis of the kinases binding sorafenib identified none other than FLT3 directly linked to IL-15 production (Supplementary Fig. 7) . On the basis of these observations, we propose a mechanism through which sorafenib increases IL-15 production via inhibition of the negative regulatory function of ATF4 in FLT3-ITD + AML, resulting in IRF7 activation (Fig. 4j) .
T cells isolated from patients responding to sorafenib exhibit increased mitochondrial fitness Like sorafenib, other FLT3 inhibitors increased IL-15 production (Supplementary Fig. 8a-q) . In accordance with our findings in mouse leukemia cells, we observed that in vitro sorafenib exposure increased IL15 mRNA levels in primary human FLT3-ITD + AML cells, but not in FLT3-ITD − AML cells (Fig. 5a-d) . Additionally, IL-15 serum levels, levels of IL-15 and p-IRF7 protein in BM, and IL15 mRNA levels in leukemia cells increased in individuals with FLT3-ITD + AML upon sorafenib treatment (Fig. 6a-c and Supplementary Fig. 9a-c) and declined when leukemia burden was reduced ( Supplementary  Fig. 9d ). We separately analyzed responders (hematologic complete remission was attained after treatment with DLI and sorafenib) and nonresponders (complete remission was not attained). The increase in IL-15 and p-IRF7 levels was not seen in nonresponders (Fig. 6a-c) , and no increase was seen for other cytokines ( Supplementary  Fig. 9e-i) . Increased IFN-γ serum levels (Fig. 6d) and increased frequency of IFN-γ + CD8 + T cells (Supplementary Fig. 9j,k) were found in DLI-sorafenib responders. Furthermore, the frequency of perforin + CD8 + T cells was increased in DLI-sorafenib responders but not in nonresponders ( Supplementary Fig. 9l,m) . Whole-genome sequencing of human primary FLT3-ITD + AML cells indicated a variable frequency of somatic mutations and copy number alterations regardless of membership in the responder or nonresponder group (Supplementary Fig. 10a-c) . Mutations conferring resistance to the FLT3 inhibitor (encoding FLT3-D839G and FLT3-D835Y 22 ) were detected in several nonresponders but not in responders (Supplementary Fig. 10d) . We annotated all mutations within a given distance of the transcription start sites of IRF family genes and found a reduction in the number of germline mutations affecting Each data point represents the IL-15 level in the serum of a patient before sorafenib (so.) treatment (day 0) and after the start of sorafenib treatment (day 3; before the patients received DLI). The dashed line indicates the detection limit (4 pg/ml) of the IL-15 ELISA. n values represent biologically independent patients. The P value was determined using the two-sided Wilcoxon matched-pairs signed-rank test. (b) Quantification of IL15 mRNA expression through qPCR of leukemia cells (>90% purity) derived from the peripheral blood of patients with FLT3-ITD + AML before (day −3) and after (day 6) the start of sorafenib treatment. Fold change is relative to the time point before sorafenib treatment, which is set as '1'. Each data point represents the ratio of IL15 to GAPDH mRNA expression from an individual patient at the indicated time point. n values represent biologically independent patients. The P value was determined using the two-sided Wilcoxon matched-pairs signed-rank test. (c) Quantification of the number of p-IRF7 + cells per high-power field (HPF) in BM biopsies from patients with FLT3-ITD + AML before (day 0) and after (day 15) the start of sorafenib treatment. Each data point represents the measurement of an individual patient at the indicated time point. n values represent biologically independent patients. The P value was determined using the two-sided Wilcoxon matched-pairs signed-rank test. (d) IFN-γ levels in serum from patients who relapsed with FLT3-ITD + AML after allo-HCT. Each data point represents the IFN-γ level in serum from a patient before (day 0) and after the start of sorafenib treatment (day 3; before the patients received DLI). n values represent biologically independent patients. The P value was determined using the two-sided Wilcoxon matched-pairs signed-rank test. (e) Heat map displaying the significance of having a smaller number of germline and somatic mutations in chromatin states marked as Tx (strong transcription) or TxW (weak transcription) around the transcription start sites of various IRF family genes for nonresponders (n = 4 biologically independent patients) versus responders (n = 4 biologically independent patients). IRF genes are hierarchically clustered by their Euclidean distance using the complete linkage algorithm. Significance of mutation frequencies was calculated from ANOVA with a post hoc Tukey's test. P values for the comparison of the different IRFs for responders versus nonresponders were as follows: IRF7, P = 0.0005; IRF5, P = 0.001 (like IRF7, IRF5 activation induces IFN responses 37 ); IRF1-IRF4 and IRF6-IRF9, not significant. (f-i) Metabolic profiling of CD8 + T cells derived from the peripheral blood of patients with FLT3-ITD + AML before (day −2) and after (day 4) the start of sorafenib treatment, following FCCP exposure. Cells were profiled for ECAR in responders (f) and nonresponders (h) and for OCR relative to the basal level in responders (g) and nonresponders (i). Each data point represents the measurement of an individual patient at the indicated time point; n values represent biologically independent patients. P values were determined using the two-sided Wilcoxon matched-pairs signed-rank test. (j) Comparison of the median DI of the TCRα and TCRβ CDR3 amino acid sequences between responders and nonresponders. The analysis was performed on CD3 + cells isolated from responders (n = 7 biologically independent patients) and nonresponders (n = 7 biologically independent patients) on day 30 after the start of sorafenib treatment. The P value was determined using the two-sided Mann-Whitney U test.
No adjustments were made for multiple comparisons.
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sites with strong (Tx) and weak (TxW) transcription around IRF7 in the AML cells of DLI-sorafenib nonresponders as compared to DLI-sorafenib responders (Fig. 6e) . The transcription start sites of IRF family genes were based on chromatin state data from monocytes. IL15 mRNA expression was upregulated after sorafenib treatment only in responders (Supplementary Fig. 11a ).
Mitochondrial spare respiratory capacity (SRC) and glycolytic capacity (GC) have been linked to prolonged T cell survival and enhanced ability to respond to antigen challenge [23] [24] [25] . To understand whether T cell metabolism in patients was linked to sorafenib responsiveness, we metabolically profiled their CD8 + T cells by measuring the oxygen consumption rate (OCR; reflecting oxidative phosphorylation) and the extracellular acidification rate (ECAR; reflecting the rate of glycolysis indicated by lactate secretion) at baseline and during a mitochondrial fitness test 23 . In DLI-sorafenib responders, both the GC and SRC were significantly enhanced following sorafenib treatment (Fig. 6f,g and Supplementary Fig. 11b,c) . In contrast, no changes in the metabolic profile were observed in DLIsorafenib nonresponders following sorafenib treatment (Fig. 6h,i and Supplementary Fig. 11d,e) .
The Shannon diversity indexes (DI) for the complementarity-determining region 3 (CDR3) amino acid sequences of the T cell receptor α (TCRα) and TCRβ chains were significantly higher in nonresponders than in responders (Fig. 6j) . This was confirmed through analysis of variable gene segment usage for both TCR chains ( Supplementary  Fig. 12a,b) . These observations are in line with previous studies showing that DLI response is linked to low diversity in the TCR repertoire 26, 27 .
A retrospective analysis of 409 patients with FLT3-ITD + AML relapse after allo-HCT showed the dismal prognosis of these patients (Supplementary Fig. 13a-f and Supplementary Tables 1-11 ).
DISCUSSION
Consistent with our data, results from others have shown that reduced IL-15 serum levels are associated with an increased risk for AML relapse after allo-HCT 28 . Graft-versus-leukemia (GVL) activity 29, 30 as well as GVHD severity [31] [32] [33] increased upon administration of IL-15 after mouse allo-HCT. To avoid toxicity from a systemic increase in IL-15, we used sorafenib, which induces IL-15 production directly in the leukemia cell itself, thereby promoting a strong GVL effect without substantial induction of GVHD. In accordance with these findings, others have reported the production of IL-15 by acute leukemia cells 34, 35 ; however, no strategy has been developed to directly increase IL-15 production in malignant cells themselves. Our observation is highly relevant clinically, as the relapse rate in patients with FLT3-ITD + AML is 52% at 3 years after allo-HCT and the prognosis for these relapsed patients is poor 36 . We also explored the previous clinical observation of a synergistic effect between sorafenib and allo-HCT in FLT3-ITD + AML 5 through delineating the immunological mechanism underlying this observation, thereby providing a scientific rationale for using sorafenib to treat patients with relapsed FLT3-ITD + AML. In agreement with our results, it was shown that individuals receiving preemptive sorafenib treatment had lower relapse rates and improved survival as compared to a control group [8] [9] [10] [11] .
Sorafenib-related IL-15 production improved the longevity phenotype of donor CD8 + T cells and their ability to induce recall immunity. The increased GC and mitochondrial SRC of CD8 + T cells from DLI-sorafenib responders with higher IL-15 serum levels are consistent with previous reports in CD8 + T cells that indicate that IL-15 promotes mitochondrial biogenesis and contributes to enhanced glycolytic response following antigen challenge 24 .
Overall, we provide mouse and human data that support a new concept for treatment of FLT3-ITD + AML relapse following allo-HCT using sorafenib and DLI in combination. We show that FLT3 inhibition reduces ATF4 expression, allowing activation of the p-IRF7-IL-15 axis in leukemia cells. This in turn promotes immune memory against tumor cells, leading to immune-mediated cure of FLT3-ITD + AML relapse. A prospective study is required to determine whether the sorafenib-DLI combination is superior to other treatments.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
ONLINE METHODS
Human subjects. Protocols for human sample collection and analysis were approved by the Institutional Ethics Review Board (IRB) of the Medical Center at the University of Freiburg, Germany (Protocol numbers: 10024/13, 26/11, 509/16 "Analysis of patients with FLT3-ITD-mutated AML after allogeneic hematopoietic cell transplantation"), and the study was registered at ClinicalTrials.gov (NCT02867891). Written informed consent was obtained from each patient. All analyses of human data were carried out in compliance with the relevant ethical regulations.
With IRB approval, we conducted a multicenter, retrospective analysis of patients with FLT3-ITD + AML who received any kind of therapy for hematological relapse after allo-HCT. We contacted the transplant programs with the highest volumes of patients with AML undergoing allo-HCT, which were provided by the European Group for Blood and Marrow Transplantation (EBMT). Additional sites in the United States, Canada, Japan, and Australia were surveyed on the basis of recommendation from these initial sites.
All data reported by the transplant centers is shown in Supplementary  Table 1 . Of the 419 patients with relapse of FLT3-ITD + AML after allo-HCT, 10 patients were excluded because they received no relapse treatment (n = 6), they had no hematological relapse (n = 1), their survival data were incomplete (n = 1), the time until second allo-HCT was unknown (n = 1), or they never entered remission after allo-HCT (n = 1). All excluded patients are displayed in Supplementary Table 1 . The resulting 409 patients with FLT3-ITD + AML relapse after allo-HCT were analyzed for response rates and OS.
The decision to treat relapse was made by the individual centers on the basis of published literature providing a scientific rationale for DLI 38-40 and DLI combined with sorafenib 5 . To date, no international guidelines or clinical pathway recommendations exist specifically for patients who relapse with FLT3-ITD + AML after allo-HCT. Sorafenib was given at a dosage of 400 mg twice daily.
The patients' characteristics, including age at treatment and sex, AML characteristics, donor type, conditioning regimen, immunosuppressive regimen, and remission status before transplant, are detailed in Supplementary  Table 1 for each patient. The data for each treatment group are summarized in Supplementary Tables 2-11. Mice. C57BL/6 (H-2Kb, Thy-1.2), BALB/c (H-2Kd, Thy-1.2), NSG, and Rag2 −/− Il2ra −/− mice were purchased from Charles River Laboratory (Sulzfeld, Germany) or Janvier Labs (France) or were taken from the local stock at the animal facility at the University of Freiburg. Il15 −/− mice were provided by Y. Tanriver (University of Freiburg). Il15ra −/− mice were provided by B. Becher (University of Zurich). Mice were between 6 and 12 weeks of age at the time of the experiments, and donor-recipient pairs that were both female or both male were used. Mouse experiments were carried out in compliance with relevant animal-use guidelines and ethical regulations. Protocols for mouse experiments (Protocol numbers: G13-116, G-15/018, G-16/018, G-17/093) were approved by the Regierungspräsidium (Federal Ministry for Nature, Environment and Consumers' Protection) Freiburg, Freiburg, Germany.
Immunologic analysis.
Correlative studies were performed before sorafenib treatment (day -3, day -2 or day 0 relative to start of sorafenib as indicated in the figure; day 0 was prior to sorafenib treatment but within the same day as start of sorafenib treatment) and on different days after the start of sorafenib treatment, as indicated in the figure legends. These studies included the following: immunophenotypic analysis of peripheral blood mononuclear cells (PBMCs) using flow cytometry; immunohistochemical staining of formalin-fixed, paraffin-embedded BM biopsy specimens; whole-exome sequencing of enriched AML cells; DNA sequencing of the TCR chains of enriched T cells; analysis of CD8 + T cell metabolism; microarray analysis of enriched AML cells; and cytokine and chemokine assays of plasma samples.
Metabolism assays (Seahorse) of human CD8 + T cells. The OCR and ECAR of human CD8 + T cells were measured in XF medium (nonbuffered RPMI-1640 containing 25 mM glucose, 2 mM L-glutamine, and 1 mM sodium pyruvate) under basal conditions and in response to 1 µM oligomycin, 1.5 µM carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP), and 100 nM rotenone + 1 µM antimycin A (all from Sigma) using a 96-well XFe Extracellular Flux Analyzer (Seahorse Bioscience) as previously described 41 .
Whole-genome sequencing. Whole-genome sequencing was performed for four tumor samples on the Illumina HiSeq X platform. Each sample was sequenced on four lanes to ensure good coverage. After trimming of poorquality reads 42 , reads were aligned to the hg19 human reference genome using Burrows-Wheeler aligner (BWA) 43 . Duplicate removal, indel realignment, and base-quality recalibration were performed using the Genome Analysis Toolkit 44 . We called SNP and indel mutations and applied false-positive filtering using VarScan 2. Relevant mutations were selected using the following criteria: read depth >8 reads per base, variant allele frequency >9%, and minor allele frequency (MAF) from the Exome Aggregation Consortium (ExAC) database 45 <0.1%. Copy number alteration analysis was performed using Control-FREEC 46 .
Gene expression analysis of responder and nonresponder patients after sorafenib treatment. RNA was extracted from PBMCs isolated from 8 ml of blood in eight patients. The blood was isolated from the same patient 3 d before start of sorafenib and 6 d after the start of sorafenib. For each sample, 2 µg of total RNA from ~10 7 cells was incubated with DNase I according to the manufacturer's instructions (Qiagen, Germany) and was cleaned up using the RNeasy Micro Kit (Qiagen, Germany). RNA integrity was analyzed by capillary electrophoresis using a Fragment Analyzer (Advanced Analytical Technologies, Inc., Ames, IA). RNA samples were further processed with the Affymetrix GeneChip Pico kit and hybridized to Affymetrix Clariom S arrays as described by the manufacturer (Affymetrix, USA). The arrays were normalized via robust multichip averaging as implemented in the R/Bioconductor oligo package 47 . Gene set enrichment was calculated using the R/Bioconductor package gage 48 with the pathways from ConsensusPathDB 49 as gene sets and a significance cutoff of P < 0.05.
Overexpression of ATF4 in Ba/F3-ITD cells.
The lentiviral vector for overexpression of mouse ATF4, mATF4 (Plasmid no. 24874), was purchased from Addgene, USA. The 293T cell line used for packaging was purchased from Clontech, France, and cultured in DMEM, high glucose supplemented with GlutaMAX, pyruvate (Gibco, Germany), 10% FCS (PAN-Biotech, Germany), and 1% penicillinstreptomycin (Gibco, Germany). The packaging cells were transiently transfected with 10 µg of mATF4 and 10 µg of envelope vector pVSV-G using CaCl 2 , and viral stocks were collected 48 and 72 h after transfection. We used these viral stocks to transduce Ba/F3-ITD cells, and the cells were cultured in 2 µg/ml puromycin (Invivogen, France) for selection of transduced cells. The overexpression of ATF4 in puromycin-selected cells was confirmed by western blotting.
Knockdown of IRF7 in MOLM-13 cells. HEK293T packaging cells were cultured as described previously 50 . Doxycycline-inducible lentiviral vectors, pTRIPZ-inducible lentiviral human IRF7-targeted shRNA (clone ID: V3THS_ 356931) and pTRIPZ-inducible lentiviral nonsilencing (NS) shRNA control (no. RHS4743) with a turboRFP reporter, were purchased from Dharmacon, Germany. Lentiviral particles were generated by transfection of HEK293T cells using polyethylenimine (Polysciences) and the Trans-Lentiviral Packaging System (Dharmacon, Germany). 5 × 10 5 MOLM-13 cells were transduced with the lentiviral particles (transfected cells are annotated as MOLM-13 NS shRNA and MOLM-13 IRF7 shRNA ). The cells were selected in 2 µg/ml puromycin (Invivogen, Germany) starting at 24 h after infection. The cells were cultured in medium containing 2 µg/ml doxycycline for 11 d to induce expression of the shRNA. Knockdown of IRF7 was confirmed by western blotting. Bone marrow transplantation model and histopathology scoring. BM transplantation experiments were performed as previously described 51, 52 . Briefly, recipients were i.v. injected with 5 × 10 6 WT BM cells after lethal irradiation using 9-11 Gy. To induce GVHD, CD4 + and CD8 + T cells were isolated from donor spleens and enriched through positive selection with the magnetic-activation cell sorting (MACS) system (Miltenyi Biotec, USA) according to the manufacturer's instructions. Anti-CD4 and anti-CD8 MicroBeads were used. CD4 + and CD8 + T cell purity was at least 90% as assessed by flow cytometry (data not shown). CD4 + and CD8 + T cells were injected at a dosage of 2 × 10 5 (C57BL/6-derived) or 5 × 10 5 (BALB/c-derived) cells i.v. on day 2 following the transplantation of BM cells with or without leukemia cells. Slides of small intestine, large intestine, and liver specimens collected after allo-HCT were stained with H&E and scored by an experienced pathologist blinded to the identity of treatment groups. GVHD severity was determined according to a previously published histopathology scoring system 53 .
Depletion of NK cells. To deplete NK cells, BM was stained for CD3 and NK1.1 surface markers. BM was depleted of NK1.1 + CD3 − cells using FACS sorting by excluding all NK1.1 + CD3 − cells.
qPCR for IL-15 expression from mouse and human cells. Mouse Ba/F3-ITD cells were treated with DMSO or different concentrations of sorafenib, tandutinib, crenolanib, midostaurin, or quizartinib for 24 h as indicated in the figure legends. Total RNA was isolated using the miRNeasy Mini Kit (Qiagen, Netherlands) or QIAzol lysis reagent (Qiagen, Netherlands) according to the manufacturer's instructions. 1 µg of total RNA from treated Ba/F3-ITD cells was reverse transcribed into cDNA using the high-capacity cDNA Reverse Transcription Kit (Thermo Scientific, USA). qPCR was carried out using the LightCycler 480 SYBR Green I Master kit (Roche, Switzerland) in a LightCyler 480 instrument (Roche, Switzerland). 50-80 ng cDNA was used for qPCR analysis. For analysis of mouse Il15 mRNA expression by Ba/F3-ITD cells, primers (sense primer: 5′-CATCCATCTCGTGCTACTT-3′, antisense primer: 5′-TTCTCCAGGTCATATCTTACAT-3′) were designed using Beacon Designer software (Premier Biosoft, UK) and were synthesized by Apara Biosciences, Germany. The reference gene was selected using the Primer Only geNorm 12-gene kit for use with SYBR Green (ge-SY-12, PrimerDesign, UK) and geNorm analysis software (PrimerDesign, USA) according to the manufacturer's instructions. Il15 mRNA expression was normalized to that of the reference gene Mon2. Mouse Il15 primers were synthesized by and purchased from Apara Biosciences, Germany, whereas Mon2 primers were purchased from PrimerDesign, USA.
For analysis of human IL15 mRNA expression, MV-411, MOLM-13 NS shRNA , MOLM-13 IRF7 shRNA , HL60, NB4, and U937 cells and human PBMCs were treated with DMSO or different concentrations of sorafenib, quizartinib, or tandutinib for 24 or 48 h as indicated in the figure legends. Cells were harvested and lysed in QIAzol lysis reagent (Qiagen, Netherlands), and total RNA was isolated according to the manufacturer's instructions. 300 ng-1 µg of total RNA was reverse transcribed into cDNA using the High-Capacity cDNA Reverse Transcription Kit (Thermo Scientific, USA). qPCR was carried out using the LightCycler 480 SYBR Green I Master kit (Roche, Switzerland) in a LightCyler 480 instrument (Roche, Switzerland). 50 ng cDNA was used for qPCR analysis. The RT − qPCR 2 Primer Assay for Human IL-15 (Qiagen, Netherlands) was used for detecting human IL15 mRNA expression. The reference gene was selected using the Primer Only geNorm 12-gene kit for use with SYBR Green (ge-SY-12, PrimerDesign, UK) and the geNorm analysis software (PrimerDesign, USA) according to the manufacturer's instruction. GAPDH was used as the reference gene (sense primer: 5′-CTCCTCCACCTTTGACGCTG-3′, antisense primer: 5′-ACCACCCTGTTGCTGTAGCC-3′) for untreated human PBMCs or human PBMCs treated with DMSO or sorafenib and for MV4-11 cells treated with DMSO or different concentrations of tandutinib or quizartinib. Human GAPDH primers were synthesized by and purchased from Apara Bioscience, Germany, or Eurofins Genomics, Germany. ENOX2 was used as the reference gene for MOLM-13 NS shRNA cells and MOLM-13 IRF7 shRNA cells, which were treated with DMSO or different concentrations of sorafenib. ENOX2 primers were purchased from PrimerDesign, USA.
Flow cytometry. All antibodies used for flow cytometry are listed in Supplementary Table 12 . For all fluorochrome-conjugated antibodies, optimal concentrations were determined using titration experiments. Cells were incubated with the respective antibodies diluted in FACS buffer for 20 min at 4 °C for surface antigen staining. Cells were then washed with FACS buffer according to the manufacturer's instructions. For mouse p-STAT5 analysis, cells were fixed with one part prewarmed 3.7% formalin and one part FACS buffer and then were exposed to 90% methanol before the p-STAT5 antibody was added. All intracellular cytokine stainings were performed using the BD Cytofix/Cytoperm kit (BD Biosciences, Germany). For intracellular cytokine staining for mouse IFN-γ, before staining, cells were restimulated with 0.5 µg/ml phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich, Germany) and 50 ng/ml ionomycin (SigmaAldrich, Germany) for 5 h, and medium containing 1 µl/ml brefeldin A (Golgi Plug, BD Biosciences, Germany) was added 2 h into restimulation. For intracellular staining of IL-15, cells were treated with medium containing 1 µl/ml brefeldin A (Golgi Plug, BD Biosciences, Germany) for 8 h before staining with unconjugated anti-IL-15 antibody (overnight staining at 4 °C). The cells were then stained with allophycocyanin (APC)-conjugated F(ab′) 2 anti-rat IgG secondary antibody (polyclonal antibody, catalog number 17-4010-82, eBioscience, Germany). For intracellular staining of human IFN-γ and perforin, cells were fixed with 4% paraformaldehyde and stained in 1× BD Perm/Wash Buffer according to the manufacturer's instructions. To exclude dead cells, the LIVE/DEAD Fixable Dead Cell Stain Kit (Molecular Probes, USA) was used according to the manufacturer's instructions. Data were acquired on a BD LSR Fortessa (BD Biosciences, Germany) or Flow Cytometer CyAn ADP (Beckman Coulter, Germany) and analyzed using FlowJo software (Tree Star, USA). The gating strategy is provided in Supplementary Figure 14. Statistical analysis. For the sample size in the mouse GVL survival experiments, a power analysis was performed. A sample size of at least n = 8 mice per group was determined by 80% power to reach statistical significance of 0.05 to detect an effect size of at least 1.06. For the xenograft model, n = 7 mice per group was used because of the greater differences expected in this experimental setting. Differences in animal survival (Kaplan-Meier survival curves) were analyzed using the Mantel-Cox test. The experiments were performed in a nonblinded fashion, except for the GVHD severity scoring. To obtain unbiased data, the histopathological scoring of GVHD severity was performed by a pathologist blinded to both the genotype and treatment group. After finalization of the quantitative GVHD severity scores, the samples were allocated to their genotypes and treatment groups. There was no randomization of mice or samples before analysis. All samples and mice were included in our analyses.
For statistical analysis, an unpaired Student's t-test (two-sided) was applied. All data were tested for normality through applying the Kolmogorov-Smirnov test. If data did not meet the criteria of normality, the Mann-Whitney U test was applied. The Wilcoxon matched-pairs signed-rank test was used to analyze related samples. Data are presented as mean ± s.e.m. (error bars). Differences were considered significant when the P value was <0.05.
Patient data were analyzed using SAS 9.2 (SAS Institute, Inc., Cary, NC, USA). OS was calculated as the time from the start of treatment until the date of death from any cause. Patients alive at the end of the observation period were censored at the time they were last seen alive. OS rates and median survival times were estimated using the Kaplan-Meier method.
Other methods. All other methods are described in the Supplementary Note. Life Sciences Reporting Summary. Further information on experimental design and reagents is available in the Life Sciences Reporting Summary. Data availability. Microarrays: GEO accession number, GSE95770; ArrayExpress accession number, E-MTAB-4487. All data are available from the authors upon reasonable request. Uncut western blots are displayed in Supplementary  Figures 15-21 
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